COMPOSITIONS AND METHODS OF USING PROTEINS AND PEPTIDES THAT BIND ANGIOGENESIS-INHIBITING PROTEINS

Abstract: The present invention relates to peptides and proteins such as receptors that bind angiogenesis-related proteins Angiostatin protein and/or Endostatin protein. Peptides and proteins of the present invention can be isolated from body fluids including blood or urine, or can be synthesized by recombinant, enzymatic or chemical methods. The peptides are particularly important for identifying receptors of angiogenesis-related proteins, as well as for identifying other proteins that regulate, transport and otherwise interact with angiogenesis-related proteins. The present invention in particular relates to laminin protein as a putative receptor for Angiostatin protein and tropomyosin as a putative Endostatin protein.

Description: COMPOSITIONS AND METHODS OF USING PROTEINS AND PEPTIDES THAT BIND ANGIOGENESIS-INHIBΓΠNG PROTEINS CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to United States Patent Application Serial No. 09/206,059 filed December 4, 1998. This application is also related to United States Provisional Patent Application Serial No. 60/150,938 filed August 26, 1999. FIELD OF THE INVENTION The present invention relates to peptides and proteins that bind angiogenesis-related proteins, such as Angiostatin protein or Endostatin protein. Peptides and proteins of the present invention can be isolated from body fluids and tissues including blood or urine, or can be synthesized by recombinant, enzymatic or chemical methods. In addition, the present invention relates to the use of such binding molecules in diagnostic assays and kits for protein measurement, histochemical kits for protein localization, nucleotide sequences coding for protein, and molecular probes for monitoring protein biosynthesis, wherein the protein is related to angiogenesis. BACKGROUND OF THE INVENTION As used herein, the term "angiogenesis" means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. The term "endothelium" means a thin layer of flat epithelial cells that lines serous cavities, lymph vessels, and blood vessels. Both controlled and uncontrolled angiogenesis are thought to proceed in a similar manner. Endothelial cells and pericytes. surrounded by a basement membrane, form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane. Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts merge with each other to form capillary loops thereby creating the new blood vessel. Persistent, unregulated angiogenesis occurs in a multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells; furthermore, unregulated angiogenesis also supports the pathological damage seen in these conditions. The diverse pathological disease states in which unregulated angiogenesis is present have been grouped together as angiogenic-dependent or angiogenic-associated diseases. The hypothesis that tumor growth is angiogenesis- dependent was first proposed in 1971. (Folkman J.. Tumor angiogenesis: Therapeutic implications., N. Engl. Jour. Med. 285: 1 182 1186, 1971) In its simplest terms it states: "Once tumor 'take' has occurred, every increase in tumor cell population must be preceded by an increase in new capillaries converging on the tumor." Tumor "take" is currently understood to indicate a prevascular phase of tumor growth in which a population of tumor cells occupying a few cubic millimeters volume and not exceeding a few million cells, can survive on existing host microvessels. Expansion of tumor volume beyond this phase requires the induction of new capillary blood vessels. For example, pulmonary micrometastases in the early prevascular phase in mice would be undetectable except by high power microscopy on histological sections. It is clear that angiogenesis plays a major role in the metastasis of a cancer. If this angiogenic activity could be repressed or eliminated, then the tumor, although present, would not grow. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system. Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases. One example of a disease mediated by angiogenesis is ocular neovascular disease. This disease is characterized by invasion of new blood vessels into the structures of the eye such as the retina or cornea. It is the most common cause of blindness and is involved in approximately twenty eye diseases. In age- related macular degeneration, the associated visual problems are caused by an ingrowth of chorioidal capillaries through defects in Bruch's membrane with proliferation of fibro vascular tissue beneath the retinal pigment epithelium. Angiogenic damage is also associated with diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma and retrolental fibroplasia. Other diseases associated with corneal neovascularization include, but are not limited to, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, osteoporosis, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca. sjogrens, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi sarcoma, Mooren ulcer, Terrien ' s marginal degeneration, mariginal keratolysis, rheumatoid arthritis, systemic lupus, polyarteritis, trauma, Wegener's sarcoidosis, Scleritis, Steven ' s Johnson disease, periphigoid radial keratotomy, and corneal graph rejection. Diseases associated with retinal/choroidal neovascularization include, but are not limited to, diabetic retinopathy. macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis. mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales disease, Bechet's disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargart's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis. trauma and post-laser complications. Other diseases include, but are not limited to, diseases associated with rubeosis (neovascularization of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy. Another disease in which angiogenesis is believed to be involved is rheumatoid arthritis. The blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction. The factors involved in angiogenesis may actively contribute to, and help maintain, the chronically inflamed state of rheumatoid arthritis. Factors associated with angiogenesis may also have a role in osteoarthritis. The activation of the chondrocytes by angiogenic-related factors contributes to the destruction of the joint. At a later stage, the angiogenic factors would promote new bone formation. Therapeutic intervention that prevents the bone destruction could halt the progress of the disease and provide relief for persons suffering with arthritis. Chronic inflammation may also involve pathological angiogenesis. Such disease states as ulcerative colitis and Crohn's disease show histological changes with the ingrowth of new blood vessels into the inflamed tissues. Bartonellosis. a bacterial infection found in South America, can result in a chronic stage that is characterized by proliferation of vascular endothelial cells. Another pathological role associated with angiogenesis is found in atherosclerosis. The plaques formed within the lumen of blood vessels have been shown to have angiogenic stimulatory activity. One of the most frequent angiogenic diseases of childhood is the hemangioma. In most cases, the tumors are benign and regress without intervention. In more severe cases, the tumors progress to large cavernous and infiltrative forms and create clinical complications. Systemic forms of hemangiomas, the hemangiomatoses, have a high mortality rate. Therapy resistant hemangiomas exist that cannot be treated with therapeutics currently in use. Angiogenesis is also responsible for damage found in hereditary diseases such as Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia. This is an inherited disease characterized by multiple small angiomas, tumors of blood or lymph vessels. The angiomas are found in the skin and mucous membranes, often accompanied by epistaxis (nosebleeds) or gastrointestinal bleeding and sometimes with pulmonary or hepatic arteriovenous fistula. Numerous efforts have been made by researchers in the pharmaceutical industry to improve the target specificity of drugs. As is familiar to those skilled in the art, the manifestation of a disease many times involves the display of a particular cell type or protein as an antigenic, epitopic, or surface marker. In such instances, an antibody can be raised against the unique cell surface marker and a drug can be linked to the antibody. Upon administration of the drug/antibody complex to a patient, the binding of the antibody to the cell surface marker results in the delivery of a relatively high concentration of the drug to the diseased tissue or organ. Similar methods can be used where a particular cell type in the diseased organ expresses a unique cell surface receptor or a ligand for a particular receptor. In these cases, the drug can be linked to the specific ligand or to the receptor, respectively, thus providing a means to deliver a relatively high concentration of the drug to the diseased organ. One of the important proteins involved in angiogenesis is Angiostatin protein, (see United States Patent No. 5,639,725 to O'Reilly et al., which is incorporated in its entirety by reference herein). Angiostatin protein preferably has a molecular weight of between approximately 38,000 Daltons and 45,000 Daltons as determined by reducing polyacrylamide gel electrophoresis, and has an amino acid sequence substantially similar to that of a plasminogen fragment beginning at approximately amino acid number 98 of an intact plasminogen molecule. Angiostatin protein has "endothelial inhibiting activity" such that it has the capability to inhibit angiogenesis in general and, for example, to inhibit the growth of bovine capillary endothelial cells in culture in the presence of fibroblast growth factor. Angiostatin protein may be produced from recombinant sources, from genetically altered cells implanted into animals, from tumors, and from cell cultures as well as other sources. Angiostatin protein can be isolated from body fluids including, but not limited to, serum and urine. Recombinant techniques include gene amplification from DNA sources using the polymerase chain reaction (PCR), and gene amplification from RNA sources using reverse transcriptase/PCR. Angiostatin protein has been shown to be capable of inhibiting the growth of endothelial cells in vitro and in vivo. Angiostatin protein does not inhibit the growth of cell lines derived from other cell types. Specifically, Angiostatin protein has no effect on Lewis lung carcinoma cell lines, mink lung epithelium, 3T3 fibroblasts, bovine aortic smooth muscle cells, bovine retinal pigment epithelium, MDCk cells (canine renal epithelium), WI38 cells (human fetal lung fibroblasts), EFN cells (murine fetal fibroblasts) and LM cells (murine connective tissue). Endogenous Angiostatin protein in a tumor bearing mouse is effective at inhibiting metastases at a systemic concentration of approximately 10 mg Angiostatin protein/kg body weight. Angiostatin protein has a specific three dimensional conformation that is defined by the kringle region of the plasminogen molecule. (Robbins, K.C., "The plasminogen- plasmin enzyme system" Hemostasis and Thrombosis, Basic Principles and Practice, 2nd Edition, ed. by Colman, R.W. et al. J.B. Lippincott Company, pp. 340-357, 1987). There are five such kringle regions, which are conformationally related motifs and have substantial sequence homology in the amino terminal portion of the plasminogen molecule. See Figure 1 for a schematic diagram of the structure of the plasminogen molecule. The amino acid sequence of the complete murine plasminogen molecule is shown in SEQ ID NO:81. A preferred amino acid sequence for human Angiostatin protein is shown in Figure 2. As used herein, "kringle 1 " means a protein derivative of plasminogen having an endothelial cell inhibiting activity, and having an amino acid sequence comprising a sequence homologous to kringle 1, exemplified by, but not limited to that of human kringle 1 corresponding to amino acid positions 1 1 to 90 (inclusive) of Angiostatin protein of SEQ ID NO: l . As used herein, "kringle 2" is exemplified by. but not limited, to amino acid positions 94 to 172 (inclusive) of Angiostatin protein of SEQ ID NO: l . As used herein, "kringle 3" is exemplified by, but not limited to, amino acid positions 185 to 263 (inclusive) of Angiostatin protein of SEQ ID NO: l. As used herein, "kringle 4" is exemplified by, but not limited to, amino acid positions 288 to 366 (inclusive) of Angiostatin protein of SEQ ID NO: l . Furthermore, it is understood that a variety of silent amino acid substitutions, additions, or deletions can be made in the above identified kringle fragments, which do not significantly alter the fragments' endothelial cell inhibiting activity, and which are, therefore, not intended to exceed the scope of the claims. Each kringle region of the plasminogen molecule contains approximately 80 amino acids and contains 3 disulfide bonds. Anti-angiogenic Angiostatin protein may contain a varying amount of amino- or carboxy-terminal amino acids from the interkringle regions and may have some or all of the naturally occurring di-sulfide bonds reduced. Angiostatin protein may also be provided in an aggregate, non-refolded, recombinant form. Additionally, individual and groups of kringle peptides may be useful for inhibition of angiogenesis (see PCT/US96/05856, which is incorporated herein by reference). The cDNA sequence for human Angiostatin protein is provided as SEQ ID NO: 29. It is contemplated that any isolated protein or peptide having a three dimensional kringle-like conformation or cysteine motif that has anti-angiogenic activity in vivo, is also an Angiostatin protein compound. The amino acid sequence of the Angiostatin protein of the present invention may vary depending upon, for example, from which species the plasminogen molecule is derived. Thus, although the Angiostatin protein of the present invention that is derived from human plasminogen has a slightly different sequence than Angiostatin protein derived from mouse, it has anti-angiogenic activity as shown in a mouse tumor model. Another important angiogenesis-related protein is Endostatin protein, (see Unites States Patent Application Serial No. 08/740, 168 and WO 97/15666 O'Reilly et al.. both of which are incorporated in their entirety by reference herein) Endostatin protein is a potent and specific inhibitor of endothelial proliferation and angiogenesis. Systemic therapy with Endostatin protein causes a nearly complete suppression of tumor induced angiogenesis. Endostatin protein has a molecular weight of approximately 18,000 to approximately 20,000 Daltons as determined by non-reduced and reduced gel electrophoresis, respectively, and is capable of inhibiting endothelial cell proliferation in cultured endothelial cells. Endostatin protein has an amino acid sequence substantially similar to a fragment of a collagen molecule and whereas it binds to a heparin affinity column, it does not bind to a lysine affinity column. Endostatin protein can be isolated from murine hemangioendothelioma EOMA. Endostatin protein may also be produced from recombinant sources, from genetically altered cells implanted into animals, from tumors, and from cell cultures as well as other sources. Endostatin protein can be isolated from body fluids including, but not limited to, serum and urine. Recombinant techniques include gene amplification from DNA sources using the polymerase chain reaction (PCR), and gene amplification from RNA sources using reverse transcriptase/PCR. Alternatively, endothelial proliferation inhibiting proteins, or Endostatin proteins, of the present invention may be isolated from larger known proteins, such as human alpha 1 type XVIII collagen and mouse alpha 1 type XVIII collagen, proteins that share a common or similar N-terminal amino acid sequence. Examples of other potential Endostatin protein source materials having similar N-terminal amino acid sequences include Bos taurus pregastric esterase, human alpha 1 type XV collagen, NAD-dependent formate dehydrogenase (EC 1.2.1.2) derived from Pseudomonas sp., si 1459 hexon protein of bovine adenovirus type 3, CELF21D12 2 F21dl2.3 Caenorhabditis elegans gene product, VAL1 TGMV AL1 protein derived from tomato golden mosaic virus, s01730 hexon protein derived from human adenovirus 12, and Saccharomyces cerevisiae. Human Endostatin can be further characterized by its preferred amino acid sequence as set forth in Figure 3 and in SEQ ID NO: 2. The preferred sequence of the first 20 amino-terminal amino acids corresponds to a C-terminal fragment of collagen type XVIII or collagen type XV. Specifically, in one embodiment the amino terminal amino acid sequence of Endostatin protein corresponds to an internal 20 amino acid peptide region found in mouse collagen alpha 1 type XVIII starting at amino acid 1 105 and ending at amino acid 1 124. The amino terminal amino acid sequence of the inhibitor also corresponds to an internal 20 amino acid peptide region found in human collagen alpha 1 type XVIII starting at amino acid 1132 and ending at amino acid 1151. The cDNA sequence for Endostatin protein is provided as SEQ ID NO: 30. Both Angiostatin protein and Endostatin protein specifically and reversibly inhibit endothelial cell proliferation and may be used, for example, as a birth control drug, for treating angiogenesis-related diseases, particularly angiogenesis- dependent cancers and tumors, and for curing angiogenesis- dependent cancers and tumors. Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of such diseases mediated by angiogenesis. Potential therapies useful for controlling angiogenic processes may involve recognition of antigenic markers and receptors associated with angiogenesis and subsequent modification of such markers and receptors. For example, once a receptor for an angiogenesis- related protein is identified, it can be blocked, thereby inhibiting the effect of the angiogenesis-related protein and ultimately reducing angiogenesis. One technique that is useful for identifying antigenic markers and receptors is phage-display technology, (see for example Phage Display of Peptides and Proteins: A Laboratory Manual. Edited by Brian K. Kay et al. Academic Press San Diego, 1996) Phage-display technology is a powerful tool for the identification of individual epitopes that interact with ligands such as proteins and antibodies. Phage peptide libraries typically comprise numerous different phage clones, each expressing a different peptide. encoded in a single-stranded DNA genome as an insert in one of the coat proteins. In an ideal phage library the number of individual clones would be 20 n , where "n" equals the number of residues that make up the random peptides encoded by the phage. For example, if a phage library was screened for a seven residue peptide, the library in theory would contain 20 (or 1.28 x 10 9 ) possible 7-residue sequences. Therefore, a 7-mer peptide library should contain approximately 10 individual phage. Phage clones displaying peptides that are able to mimic epitopes recognized by a particular protein (or antibody), are selected from the library based upon their binding affinity to that protein (or antibody), and the sequences of the inserted peptides are deduced from the DNA sequences of the phage clones. This approach is particularly desirable because no prior knowledge of the primary sequence of the target protein is necessary, epitopes represented within the target, either by a linear sequence of amino acids (linear epitope) or by the spatial juxtaposition of amino acids distant from each other within the primary sequence (conformational epitope) are both identifiable, and peptidic mimotopes of epitopes derived from non- proteinaceous molecules such as lipids and carbohydrate moieties can also be generated. With regard to angiogenesis-related disease, it is evident that angiogenesis-related proteins such as Angiostatin protein and Endostatin protein play an important role in the development of disorders such as cancer. What is needed therefore, is the development of methods and compositions for the identification of receptors and molecules that bind such proteins. The identification of such receptors and molecules would facilitate the understanding of angiogenesis-related protein influence and interaction, and consequently enable the development of drugs to modify the activity of these proteins as necessary. SUMMARY OF THE INVENTION In accordance with the present invention, compositions and methods are provided that are effective for modulating angiogenesis, and inhibiting all forms of unwanted angiogenesis. especially angiogenesis related to tumor growth. Specifically, the present invention includes peptides and proteins that bind to angiogenesis-related peptides and proteins, such as Angiostatin protein or Endostatin protein. Identification of these binding molecules and proteins has improved the understanding of angiogenesis-related protein influence, and has also made possible the development of therapeutic agents for modifying angiogenesis associated with disorders such as cancer and tumor development. Angiostatin protein and Endostatin protein are defined by their ability to inhibit the angiogenic activity of endogenous growth factors such as bFGF on endothelial cells, in vitro and tumor growth in vivo. Angiostatin protein contains approximately kringle regions 1 through 4 of plasminogen and is a protein having a molecular weight of between approximately 38,000 Daltons and 45,000 Daltons as determined by reducing polyacrylamide gel electrophoresis. In a preferred embodiment, Angiostatin protein has an amino acid sequence substantially similar to that of a fragment of murine plasminogen beginning at amino acid number 98. Endostatin protein is a collagen fragment, and is a protein having a molecular weight of between approximately 18,000 Daltons and 20,000 Daltons as determined by non- reducing and reducing gel electrophoresis, respectively. Endostatin protein is further characterized by its ability to bind a heparin affinity column and inability to bind a lysine affinity column. A preferred sequence of the first 20 N-terminal amino acids of Endostatin protein corresponds to a C-terminal fragment of collagen type XVIII or XV. The present invention also encompasses nucleotide sequences encoding peptides and proteins that bind angiogenesis- related peptides and proteins, as well as expression vectors containing nucleotide sequences encoding such binding peptides and proteins, and cells containing one or more expression vectors containing nucleotide sequences encoding such peptides and proteins. The present invention further encompasses gene therapy methods whereby nucleotide sequences encoding angiogenesis- related protein binding peptides and proteins are introduced into a patient to modify in vivo Angiostatin protein or Endostatin protein levels. The present invention also includes diagnostic methods and kits for detection and measurement of peptides and proteins that bind angiogenesis-related proteins in biological fluids and tissues, and for localization of such peptides and proteins in tissues and cells. The diagnostic method and kit can be in any configuration well known to those of ordinary skill in the art. The present invention includes peptides and proteins that bind Angiostatin protein or Endostatin protein and cause the transmission of an appropriate signal to a cell and act as agonists or antagonists of angiogenesis. In addition, the present invention includes fragments of proteins that bind angiogenesis-related proteins, and analogs thereof, that can be labeled isotopically, or with other molecules or proteins, for use in the detection and visualization of angiogenesis-related protein binding sites with techniques, including, but not limited to, positron emission tomography, autoradiography, flow cytometry, radioreceptor binding assays, and immunohistochemistry. The peptides and analogs of the present invention also act as agonists and antagonists for Angiostatin protein or Endostatin protein receptors, thereby enhancing or blocking the biological activity of Angiostatin protein or Endostatin protein. Such peptides and proteins are used in the isolation of Angiostatin protein or Endostatin protein receptors. The present invention includes molecular probes for the ribonucleic acid and deoxyribonucleic acid involved in transcription and translation of angiogenesis-related protein binding peptides and proteins. These molecular probes provide means to detect and measure angiogenesis-related protein biosynthesis in tissues and cells. Accordingly, it is an object of the present invention to provide compositions and methods comprising peptides and proteins that bind angiogenesis-related peptides and proteins. It is another object of the present invention to provide compositions and methods for treating diseases and processes that are mediated by angiogenesis. It is yet another object of the present invention to provide diagnostic or prognostic methods and kits for detecting the presence and amount of angiogenesis-related protein binding peptides in a body fluid or tissue. It is yet another object of the present invention to provide compositions and methods for treating diseases and processes that are mediated by angiogenesis including, but not limited to, hemangioma, solid tumors, blood borne tumors, leukemia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, Crohn's disease, plaque neovascularization, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, fractures, keloids, vasculogenesis. hematopoiesis, ovulation, menstruation, placentation, and cat scratch fever. It is another object of the present invention to provide compositions and methods for treating or repressing the growth of a cancer. Another object of the present invention to provide compositions and methods for the detection or prognosis of cancer. It is another object of the present invention to provide compositions and methods for use in visualizing and quantitating sites of Angiostatin protein or Endostatin protein binding in vivo and in vitro. It is yet another object of the present invention to provide compositions and methods for use in detection and quantification of Angiostatin protein or Endostatin protein biosynthesis. Another object of the present invention to provide receptors that bind angiogenesis-related proteins, such as Angiostatin protein or Endostatin protein. Yet another object of the present invention is to identify proteins, and fragments thereof, that interact and regulate the activity of angiogenesis-related proteins such as Angiostatin protein or Endostatin protein. Still another object of the present invention is to provide proteins, and fragments thereof, that are involved in the transport of angiogenesis-related proteins such as Angiostatin protein or Endostatin protein. Another object of the present invention is to provide proteins, and fragments thereof that function as substrates through which angiogenesis-related proteins exert their activities. It is yet another object of the present invention to provide a therapy for cancer that has minimal side effects. Yet another object of the present invention is to provide methods and compositions comprising proteins and peptides, that bind Angiostatin protein comprising laminin protein, and/or proteins and peptides that bind Endostatin protein comprising tropomyosin. Still another object of the present invention is to provide methods and compositions comprising peptides, that bind Angiostatin protein and/or Endostatin protein, linked to a cytotoxic agent for treating or repressing the growth of a cancer. It is another object of the present invention to provide fusion proteins comprising laminin and tropomyosin for binding and regulating Angiostatin protein and/or Endostatin protein. Yet another object of the present invention is to provide fusion proteins comprising peptides or proteins that bind Angiostatin protein and/or Endostatin protein. Another object of the present invention is to provide methods and compositions for targeted delivery of angiogenesis- related protein compositions to specific locations. Yet another object of the invention is to provide compositions and methods useful for gene therapy for the modulation of angiogenic processes. These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows a schematic representation of the structure of human plasminogen and its kringle fragments. Human plasminogen is a single chain protein containing 791 amino acids with one site of N-linked glycosylation at Asn^89 The non-protease region of human plasminogen consists of the N- terminal 561 amino acids existing in five separate domains, termed kringles as shown in circles (Kl, K2, K3, K4 and K5), along with the protein sequences (or with the amino acids) that separate these structures. Each triple disulfide bonded kringle contains approximately 80 amino acids. Angiostatin covers the first 4 of these kringle domains (Kl-4), kringle 3 (Kl-3) and kringle 4 (K4) are obtained by digestion of human plasminogen with elastase. The rest of the kringle fragments are recombinant proteins expressed in E. coli. 'SS' signifies signal sequence. 'PA' signifies preactivation protein. Figure 2 shows the preferred amino acid sequence of human Angiostatin protein. Figure 3 shows the preferred amino acid sequence of human Endostatin protein. Figure 4 provides graphs demonstrating binding preference of linear peptides (selected by display technology) for Angiostatin protein over plasminogen. Figure 5 provides graphs demonstrating binding preference of cyclized peptides (selected by display technology) for Angiostatin protein over plasminogen. Figure 6A provides the complete amino acid sequence of laminin protein (SEQ ID NO: 113), and Figure 6B provides the complete nucleotide sequence of laminin protein (SEQ ID: 1 14). Figure 7 shows the three motifs of laminin protein corresponding to Angiostatin protein selected peptides in a single 60 amino acid long region. Figure 8 is a graph showing the results of an ELISA assay demonstrating the interaction of tropomyosin and Endostatin protein. Figure 9 provides the results of an in vivo experiment for assessing the interaction of peptide E37 and Endostatin protein. Figure 10 provides a graph showing the results of an in vivo experiment for assessing the interaction of peptide E37 and Endostatin protein as the mean, standard deviation, T/C and the results of a 2-tailed T-test. DETAILED DESCRIPTION The following description includes the best presently contemplated mode of carrying out the invention. This description is made for the purpose of illustrating the general principles of the inventions and should not be taken in a limiting sense. All references listed or cited herein are incorporated by reference in their entirety. As used herein, the term "Angiostatin protein" refers to a protein containing approximately kringle regions 1 through 4 of a plasminogen molecule and having a molecular weight of between approximately 38,000 Daltons and 45,000 Daltons as determined by reducing polyacrylamide gel electrophoresis. Angiostatin protein preferably has an amino acid sequence substantially similar to that of a fragment of murine plasminogen beginning at approximately amino acid number 98. The description of Angiostatin protein is provided in United States Patent No. 5,639,725 to O'Reilly et al. A preferred amino acid sequence for human Angiostatin protein is shown in Figure 3. As used herein, the term "Endostatin protein" refers to a protein that is a collagen molecule fragment and has a molecular weight of between approximately 18,000 Daltons and 20,000 Daltons as determined by non-reducing and reducing electrophoresis, respectively. The preferred sequence of the first 20 N-terminal amino acids of Endostatin protein corresponds to a C-terminal fragment of collagen type XVIII or XV. The description of Endostatin protein is provided in Unites States Patent Application Serial No. 08/740, 168 and WO 97/15666 O'Reilly et al. A preferred amino acid sequence for human Endostatin protein is shown in Figure 3. As used herein, the term "angiogenesis-related protein" refers to Angiostatin protein and Endostatin protein, and active fragments and homologs thereof, involved in blood vessel growth and development. The term "angiogenesis-related protein" includes proteins that are animal or human in origin and also includes proteins that are made synthetically by chemical reaction, or by recombinant technology in conjunction with expression systems. As used herein, the term "binding peptide" refers to peptides, active fragments and homologs thereof, that bind angiogenesis-related proteins. It will be understood by those skilled in the art that the preferred binding peptides include peptide analogs, which are defined herein as peptides capable of binding angiogenesis-related proteins. Exemplary binding peptides, their amino acid sequences (SEQ ID NOS: 3-28, SEQ ID NOS: 31-42 and 82-113), and their experimental abbreviations are set forth in the description below. The binding peptides and proteins herein are other than naturally occurring immunoglobulin antibody molecules. The terms "a", "an" and "the" as used herein are defined to mean "one or more" and include the plural unless the context is inappropriate. As employed herein, the phrase "biological activity" refers to the functionality, reactivity, and specificity of compounds that are derived from biological systems or those compounds that are reactive to them, or other compounds that mimic the functionality, reactivity, and specificity of these compounds. Examples of suitable biologically active compounds include enzymes, antibodies, antigens and proteins. The term "bodily fluid," as used herein, includes, but is not limited to, saliva, gingival secretions, cerebrospinal fluid, gastrointestinal fluid, mucous, urogenital secretions, synovial fluid, blood, serum, plasma, urine, cystic fluid, lymph fluid, ascites, pleural effusion, interstitial fluid, intracellular fluid, ocular fluids, seminal fluid, mammary secretions, and vitreal fluid, and nasal secretions. 1 o Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one having ordinary skill in the art to which this invention belongs. Although other materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. The present invention includes methods and compositions for the detection and treatment of diseases and processes that are mediated by or associated with angiogenesis. The compositions comprise peptides, proteins, active fragments, and homologs thereof, that are capable of binding to angiogenesis- related proteins. In particular, the peptides and proteins of the present invention are capable of interacting with or binding to Angiostatin protein and/or Endostatin protein. The present invention includes the use of peptides and proteins such as receptors, that bind angiogenesis-related proteins for detection of angiogenesis-related proteins, such as Angiostatin protein and Endostatin protein, in body fluids and tissues for the purpose of diagnosis or prognosis of diseases such as cancer. In addition, the present invention also includes the detection of Angiostatin protein and Endostatin protein binding sites and receptors in cells and tissues. The present invention further includes methods of treating or preventing angiogenic diseases and processes including, but not limited to, arthritis and tumors by using angiogenesis protein-binding peptides and proteins for altering the production, administration and activity of Angiostatin protein or Endostatin protein. It is to be understood that the proteins and peptides that bind angiogenesis-related proteins such as Angiostatin protein or Endostatin protein can be animal or human in origin. Such binding peptides can also be produced synthetically by chemical reaction or by recombinant techniques in conjunction with expression systems. Angiogenesis-related proteins can be isolated from body fluids including, but not limited to, serum, urine and ascites, or synthesized by chemical or biological methods (including cell culture, recombinant gene expression, peptide synthesis). The proteins may also be obtained by in vitro enzymatic catalysis of plasminogen or plasmin to yield active Angiostatin protein, or of collagen to yield active Endostatin protein. Amino acid sequences of preferred peptides and proteins that bind Angiostatin protein or Endostatin protein are provided as SEQ ID NOS: 3-28, 31-42 and 82- 113. Recombinant techniques include gene amplification from DNA sources using the polymerase chain reaction (PCR), and gene amplification from RNA sources using reverse transcriptase/PCR. General references for methods that can be used to perform the various PCR and cloning procedures described herein can be found in Molecular Cloning: A Laboratory Manual (Sambrook et al., eds. Cold Spring Harbor Lab Publ. 1989, latest edition), which is hereby incorporated by reference. Both Angiostatin protein and Endostatin protein inhibit the growth of blood vessels into tissues such as unvascularized or vascularized tumors. The present invention further encompasses compositions and methods comprising, vectors containing nucleotide sequences encoding peptides and proteins capable of binding angiogenesis-related proteins comprising Angiostatin protein or Endostatin protein, wherein the vector is capable of expressing such binding peptides when present in a cell, a composition comprising a cell containing such a vector. Nucleotide sequences of preferred peptides and proteins that bind Angiostatin protein or Endostatin protein are provided as SEQ ID NOS: 43-80. Because of degeneracy in the genetic code, alternative nucleotide sequences can code for a peptide with the same sequence. The present invention further includes a method comprising, implanting into a human or non-human animal, a cell containing such a vector. The present invention also encompasses gene therapy whereby genes encoding peptides that bind angiogenesis-related proteins, such as Angiostatin protein or Endostatin protein, are regulated in a patient. Various methods of transferring or delivering DNA to cells for expression of the gene product protein, otherwise referred to as gene therapy, are disclosed in Gene Transfer into Mammalian Somatic Cells in vivo, N. Yang, Crit. Rev. Biotechn. 12(4): 335-356 ( 1992), which is hereby incorporated by reference. Gene therapy encompasses incorporation of DNA sequences into somatic cells or germ line cells for use in either ex vivo or in vivo therapy. Gene therapy functions to replace genes, augment normal or abnormal gene function, and to combat infectious diseases and other pathologies. Methods for treating medical problems with gene therapy include therapeutic strategies such as identifying the defective gene and then adding a functional gene to either replace the function of the defective gene or to augment a slightly functional gene; or prophylactic strategies, such as adding a gene for the product protein that will treat the condition or that will make the tissue or organ more susceptible to a treatment regimen. As an example of a prophylactic strategy, a gene for a peptide or protein comprising for example, laminin protein that binds to Angiostatin protein, and/or tropomyosin that binds Endostatin, may be placed in a patient to modify the occurrence of angiogenesis. Many protocols for transfer of peptide DNA or peptide regulatory sequences are envisioned in this invention. Examples of such technology is found in Transkaryotic Therapies, Inc., of Cambridge, Massachusetts, using homologous recombination to insert a "genetic switch" that turns on an erythropoietin gene in cells. See Genetic Engineering News, April 15, 1994. Such "genetic switches" could be used to activate the desired peptide in cells not normally expressing the corresponding gene. Gene transfer methods for gene therapy fall into three broad categories-physical (e.g., electroporation, direct gene transfer and particle bombardment), chemical (lipid-based carriers, or other non-viral vectors) and biological (virus-derived vector and receptor uptake). Gene therapy methodologies can also be described by delivery site. Fundamental ways to deliver genes are familiar to those skilled in the art and include ex vivo gene transfer, in vivo gene transfer, and in vitro gene transfer. Chemical methods of gene therapy may involve a lipid based compound (such as lipofectins or cytofectins), not necessarily a liposome, to ferry the DNA across the cell membrane. Another chemical method may use receptor-based endocytosis. which involves binding a specific ligand to a cell surface receptor and enveloping and transporting it across the cell membrane. The ligand binds to the DNA and the whole complex is transported into the cell. The ligand gene complex is injected into the blood stream and then target cells that have the receptor will specifically bind the ligand and transport the ligand-DNA complex into the cell. Many gene therapy methodologies employ viral vectors to insert genes into cells. For example, altered retrovirus vectors have been used in ex vivo methods to introduce genes into peripheral and tumor-infiltrating lymphocytes, hepatocytes, epidermal cells, myocytes, or other somatic cells. These altered cells are then introduced into the patient to provide the gene product from the inserted DNA. Viral vectors have also been used to insert genes into cells using in vivo protocols. To direct tissue-specific expression of foreign genes, cis-acting regulatory elements or promoters that are known to be tissue specific can be used. Alternatively, this can be achieved using in situ delivery of DNA or viral vectors to specific anatomical sites in vivo. A viral vector can be delivered directly to the in vivo site, by a catheter for example, thus allowing only certain areas to be infected by the virus, and providing long-term, site specific gene expression. In vivo gene transfer using retrovirus vectors has also been demonstrated in mammary tissue and hepatic tissue by injection of the altered virus into blood vessels leading to the organs. Fundamental advantages of retroviral vectors for gene transfer include efficient infection and gene expression in most cell types, precise single copy vector integration into target cell chromosomal DNA, and ease of manipulation of the retroviral genome. According to the methods used herein, a library of phage displaying potential binding peptides was incubated with immobilized angiogenesis-related proteins to select clones encoding recombinant peptides that specifically bound the immobilized angiogenesis-related protein. The phage that encoded the recombinant peptides were amplified after three rounds of biopanning (binding to the immobilized angiogenesis- related proteins) and individual viral plaques, each expressing a "> ~> different recombinant protein, or binding peptide, were then expanded to produce amounts of peptides sufficient to perform a binding assay. One possible technique for identifying the angiogenesis-related binding peptides involves the method wherein the DNA encoding recombinant binding peptides can be subsequently modified for ligation into a eukaryotic protein expression vector. This modification entails removal of the 5 ' secretion signal sequence and the addition of a translation initiation codon that direct translation of the recombinant binding peptide. Stop codons are also incorporated into the construct in a region downstream of the coding sequence. All cloning procedures employed in the development of the present invention were carried out according to standard laboratory practice. Methods for preparing libraries containing diverse population of various types of molecules such as peptides, polypeptides. protein, and fragments thereof are known in the art and are commercially available (see, for example, Ecker and Crooke, Biotechnology 13:351-360 (1995). and the references cited therein). The phage display libraries used in for present invention include the Ph.D. -7 phage display library (New England BioLabs Cat #8100), a combinatorial library consisting of random peptide 7-mers. The Ph.D. -7 phage display library consists of linear 7-mer peptides fused to the pill coat protein of Ml 3 via a Gly-Gly-Gly-Ser flexible linker. The library contains 2.8 x 10 9 independent clones and is useful for identifying targets requiring binding elements concentrated in a short stretch of amino acids. Another phage display library used for the present invention includes the Ph.D.-C7C library (New England BioLabs Cat # 8120) which is a combinatorial library consisting of random peptide 7-mers flanked by cysteine residues that under non- denaturing conditions are disulfide bonded resulting in the display of cyclized peptides. In non-reducing conditions, the cysteines form a disulfide bond resulting in each peptide being constrained in a disulfide loop. The library contains 3.7 x 10 independent clones that like the Ph.D. -7 library the peptides are fused to the pill coat protein of Ml 3 via a Gly-Gly-Gly-Ser flexible linker. Constrained libraries are useful in the identification of structural epitopes. This library was screened for the binding of 7 amino acid cyclized peptides. Phage selection was conducted according to methods known in the art and according to manufacturers' recommendations. The "target" proteins, recombinant human Angiostatin protein, or recombinant human Endostatin protein, were coated overnight onto tissue culture plates in humidified containers. In the first round of panning approximately 2x10 phage were incubated on the protein coated plate for 60 minutes at room temperature while rocking gently. The plates were then washed several times using standard wash solutions such as TBS (50mM Tris-HCl (pH 7.5), 150 mM NaCl) containing 0.1% Tween 20. The binding phage were then collected and amplified following elution using the target protein. Secondary and tertiary pannings were performed as necessary. Following the last screening individual colonies of phage-infected bacteria were picked at random, the phage DNA was isolated and subjected to automated dideoxy sequencing. The sequence of the displayed peptides were deduced from the DNA sequence. Use of phage-display technology is particularly desirable for the detection of molecules that function as receptors for angiogenesis-related proteins. For example, a specific receptor may be displayed on the surface of the phage such that it may bind its ligand. The receptor can then be modified by, for example, in vitro mutagenesis and variants having higher binding affinity for the ligand selected. As used herein, the term "receptor" means molecule that binds a specific, or group of specific angiogenesis-related proteins. The natural "receptors" could be expressed on the surface of a population of cells, or they could be the extracellular domain of such a molecule (whether such a form exists naturally or not), or a soluble molecule performing natural binding function in the plasma, or within a cell or organ. Alternatively, the phage-receptor can be used as the basis of a rapid screening system for the binding of ligands such as Angiostatin protein and Endostatin protein, altered ligands, or ---.4 potential drug candidates. The advantages of this system namely, of simple cloning, convenient expression, standard reagents and easy handling makes the drug screening application particularly attractive. In addition, the phage-receptor may be used to identify binding peptides and proteins for better understanding, and ultimately modifying, the role of angiogenesis-related proteins in angiogenesis, and in the manifestation of angiogenesis- related disease. For example, the binding peptides may be used to identify proteins that interact with, and/or regulate (either positively or negatively), the activity of angiogenesis-related proteins such as Angiostatin protein or Endostatin protein. In addition, such binding peptides may also be used to identify other proteins and molecules involved in the transport of angiogenesis- related proteins, and substrates through which angiogenesis- related proteins exert their activities. Following synthesis of the peptides and proteins that bind angiogenesis-related proteins, the peptides and proteins may be added to the in vitro assays to further determine the biological activity of Angiostatin protein or Endostatin protein. These assays are familiar to those skilled in the art and include HUVEC and BCE proliferation assays, HUVEC wound/migration assay, endothelial cell tube forming assay, CAM assay, Matrigel invasion assay and the rat aortic assay. Specifically, the peptides and proteins that inhibit or stimulate the activity of Angiostatin protein or Endostatin protein are identified. The ability of a peptide or protein to inhibit or stimulate the activity of either Angiostatin protein or Endostatin protein in these assays would indicate that the peptide or protein is able to mimic the interaction of Angiostatin protein or Endostatin protein with proteins that regulate their activity. The biological activity of the binding peptides and proteins may also be tested in vivo. The peptides or proteins may be pre-incubated with their target angiogenesis-related protein (Angiostatin protein or Endostatin protein) prior to being used in either the B 16B16 metastasis assay or the Lewis Lung Carcinoma primary tumor or metastasis assays. In such experiments a comparison would be made between the activity of the target protein Angiostatin protein or Endostatin protein and the target protein Angiostatin protein or Endostatin protein pre-bound with the peptide or protein. If the peptide/target protein interactions mimic important biological interactions involved in the activity of Angiostatin protein or Endostatin protein then it would be expected that the anti-angiogenic activity of the target protein would be neutralized by the binding of the peptide or protein. A complementary approach to determining whether the peptides or proteins mimic the epitopes of proteins that interact with Angiostatin protein or Endostatin protein would be to use the synthesized peptide and protein to generate antibodies. These anti-peptide and anti-protein antibodies would recognize proteins with which Angiostatin protein or Endostatin protein interact. By binding to sites important for the interaction of Angiostatin protein or Endostatin protein with their binding proteins these antibodies would effect the anti-angiogenic activity of the Angiostatin protein or Endostatin protein. Thus, these anti- peptide and anti-protein antibodies can be assayed for their ability to affect the activity of Angiostatin protein or Endostatin protein. The anti-peptide and anti-protein antibodies may also be used to screen phage expression libraries such as a λgtl l expression library. Such an approach would enable the cloning of the cDNA corresponding to proteins that interact with Angiostatin protein or Endostatin protein. Once the cDNAs have been identified they may be produced using recombinant technology and their anti-angiogenic activities in various assays determined alone and in combination with their target angiogenesis-related protein. Using the methods described above and further described below in the Examples, the peptides in Tables 1-4 have been identified as linear or cyclized peptides that bind Angiostatin protein or Endostatin protein. Two phage-display libraries were screened, the first was a linear library that encoded for linear 7 residue peptides, and the second was a disulfide constrained peptide library. Specifically, the second library consisted of 7-mer randomized peptide sequences which were flanked by a pair of cysteine residues. The cysteine residues spontaneously form disulfide cross-links, resulting in the phage displaying cyclized peptides. Table 1 Linear Peptides Binding Angiostatin Protein Table 2 Cyclized Peptides Binding Angiostatin Protein Table 3 Linear Peptides Binding Endostatin Protein Table 4 Cyclized Peptides Binding Endostatin Protein Table 5 Linear Peptides that Preferentially Bind to Angiostatin protein over Plasminogen Table 6 Cyclized Peptides that Preferentially Bind to Angiostatin protein over Plasminogen Nucleic acid sequences corresponding to the above amino acid sequences are provided as SEQ ID NOS: 43-80. The present invention encompasses the peptides set forth in Tables 5 and 6 which preferentially bind to Angiostatin protein as opposed to plasminogen. The preferential binding activity of the peptides illustrate that a preferred Angiostatin protein receptor is one of these peptides. In addition, the present invention is related to proteins which share homologous sequences to the claimed peptides. Such proteins include human possible global transcription activator, phosphopentomutase. ribonuclease RH precursor, soybean early nodulin, JNK activating kinase 1 , IL-12 beta chain, glutathione reductase, soy bean trypsin inhibitor (kunitz). fibroblast growth factor-6. chemotaxis protein, annexin XI, WEE 1, RAS suppressor protein 1, ATP synthase gamma chain, thioredoxin, collagenese, glycoprotein B- l precursor, dehydroquinate dehydratase, complement component C8 beta chain, ornithine decarboxylase antizyme, adenylate cyclase. and ATP synthase, alpha chain. The homology searches for the present invention were conducted using the FASTA sequence similarity search. The peptide sequences were queried against the SwissProt data base using the default setting (ktup 2, and BLOSUM50 for the scoring matrix). The searches were conduced using the world wide web at site http://www.fasta.genome.ad.jp/. as described by W.R. Pearson & D.J. Lipman PNAS 85:2444-2448 (1988). Following identification of the peptides described in Tables 1-6 above, further analysis was conducted in order to determine peptides that represent potential receptors, or fragments thereof, that bind Angiostatin protein or Endostatin protein. A discussion of such peptides is provided below and in the Examples. Proteins and Peptides that Bind Angiostatin Protein The present invention is particularly related to methods and compositions comprising basement membranes including, but not limited to, laminin protein for modulating angiogenesis, and inhibiting forms of unwanted angiogenesis, especially angiogenesis-related to tumor growth. As demonstrated in the Examples below, as a result of sequence similarities between peptides that bind Angiostatin protein (as identified by phage display techniques) and laminin protein (specifically Example 7), laminin protein is considered to comprise a receptor, or a molecule closely related to a receptor, for Angiostatin protein. In addition, laminin protein may also be considered a protein that is involved in mediating activity of Angiostatin protein. Based on the findings of the present invention, it is believed that Angiostatin protein interacts with the beta-1 chain of laminin protein. Laminin is a basement membrane derived noncollagenous glycoprotein found in the extracellular matrix which binds type IV collagen, glycosaminoglycan and heparin, and is involved in the promotion of cellular adhesion. Laminin protein is a heterotrimeric molecule with an alpha, beta and gamma chain. The amino acid sequence of laminin protein is set forth in Figure 6A (SEQ ID NO: 1 13) and the nucleotide sequence is set forth in Figure 6B (SEQ ID NO: 114). Proteins and Peptides that bind Endostatin protein The present invention is particularly related to methods and compositions comprising tropomyosin for modulating angiogenesis, and inhibiting forms of unwanted angiogenesis. especially angiogenesis-related to tumor growth. As demonstrated in the Examples below (specifically Examples 5, 6, 8 and 9), tropomyosin is considered to comprise a receptor, or a molecule closely related to a receptor, for Endostatin protein. In addition, tropomyosin may also be considered a protein that is involved in mediating activity of Endostatin protein. Though not wishing to be bound by the following theory, it is thought that the E37 peptide is a mimotope of a portion of the tropomyosin protein. Specifically, the 3 dimensional shape of the E37 peptide is similar to a (3 dimensional) region of the tropomyosin protein. Mimotopic homology may be characterized as 'shape homology'. As is known by those skilled in the art, because of 3 dimensional folding of proteins, epitopes are not always comprised of linear stretches of protein sequence. Such epitopes can be mimicked by linear sequences whose shape corresponds to shape of a non-linear epitope, such peptides are said to be minotopes. An important finding of the present invention is that the E37 peptide comprises a mimotope of the actual ligand binding site of tropomyosin. Accordingly, the findings of the present inventors suprisingly define not only the Endostatin protein receptor, but also define J O the actual ligand binding domain as represented by the E37 peptide. As further detailed in the Examples, both in vitro and in vivo experiments demonstrate that tropomyosin comprises the receptor, or a molecule closely related to the receptor for Endostatin protein. Antibodies against the E37 peptide have shown that the E37 peptide and tropomyosin share a common epitope, and it is believed that by virtue of this epitope Endostatin protein and tropomyosin are binding and that the anti-angiogenic activity of Endostatin protein is mediated via this interaction. Furthermore, in vivo experiments support this conclusion as the anti-tumor activity of Endostatin protein is significantly decreased in the presence of the E37 peptide. Though not wishing to be bound by the following theory, further support for the binding of tropomyosin and Endostatin protein and the consequences of this interaction on angiogenesis may be derived from the effect of such binding on pericytes. After endothelial cells form new blood vessels by angiogenesis they are immature and relatively unstable (they can regress and be remodeled readily). As the blood vessels become more mature and stable they associate with pericytes, which form a barrier around the endothelial cells. At some point during this process the pericytes differentiate into fibroblasts. There is some evidence that vessels associated with pericytes cannot regress and that this may explain why anti-angiogenic compounds like Angiostatin protein and Endostatin protein target the vasculature of tumors and not the blood vessels necessary for maintenance of vital organs. Endostatin protein results in an inhibition of proliferation of PDGF-BB or 20% fetal calf serum stimulated primary cultures of pericytes and to a lesser extent fibroblasts. More specifically, Endostatin protein results in a consistent reduction in thymidine incorporation into primary cultures of pericytes and to a lesser degree fibroblasts, that are stimulated to proliferate in response to PDGF-BB or 20% fetal calf serum. The results have been confirmed using a MTT proliferation kit. Furthermore, Endostatin protein does not appear to effect the differentiation of pericytes to fibroblasts, although inhibition of proliferation varies depending to the degree of differentiation along the pericyte/fibroblast differentiation pathway. Endostatin protein tends to have a greater effect on cells in the earlier stages of differentiation. While such cells constitute a small fraction of the total number, inhibiting their proliferation may have significant effects on the final total cell number. Endostatin protein's effect on cells early in the differentiation pathway results in a reduction of 70-80% of the final cell number. Endostatin protein also changes the morphology of these cells. The isoform of tropomyosin (there are over 20 different isoforms (types) of tropomyosin expressed by mammalian cells) initially identified as binding to Endostatin protein was fibroblast tropomyosin. Though not wishing to be bound by the following theory, it is believed that tropomyosin is involved in the mechanism of action of Endostatin protein and therefore pericytes are being inhibited by virtue of the fact that they are expressing fibroblast tropomyosin. Endostatin protein does not bind human cardiac tropomyosin indicating that not all isoforms of tropomyosin bind Endostatin protein. Consequently the cell-type specificity of Endostatin protein may be explained by the isoforms of tropomyosin that it expresses. We also have evidence that Endostatin protein will bind to the surface of fibroblasts. Though not wishing to be bound by the following theory, it is believed that as a result of the the interaction between Endostatin protein and tropomyosin, Endostatin protein inhibits pericyte differentiation and channels these cells into the apoptotic pathway. This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims. EXAMPLES EXAMPLE 1 Identification of Angiogenesis-Related Binding Peptides A "phage-display library" is a protein expression library, constructed in a vector that expresses a collection of cloned protein sequences as fusions with a phage coat protein. Thus, in the context of the present invention, single-chain recombinant proteins having the potential ability to bind angiogenesis-related proteins, are expressed as fusion proteins on the exterior of the phage particle. This "placement" advantageously allows contact and binding between the recombinant binding protein and an immobilized protein such as Angiostatin protein or Endostatin protein. Phage that bind an angiogenesis-related protein can be recovered; individual phage can then be cloned and the peptide expressed by cloned phage can be determined. Phage clones expressing binding peptides specific for angiogenesis-related proteins can be substantially enriched by serial rounds of phage binding to the immobilized protein and amplification by growth in bacterial host cells. Methods for preparing libraries containing diverse population of various types of molecules such as peptides, polypeptides, protein, and fragments thereof are well known in the art and are commercially available (see, for example, Ecker and Crooke. Biotechnology 13:351 -360 (1995), and the references cited therein, each of which is incorporated herein by reference). Where a molecule is a peptide, protein or fragment thereof, the molecule can be produced in vitro directly or can be expressed from a nucleic acid, which is produced in vitro. Methods of synthetic peptide and nucleic acid chemistry are well known to those skilled in the art. A library of molecules also can be produced, for example, by constructing a cDNA expression library from mRNA collected from a cell, tissue, organ or organism of interest. Methods for producing such libraries are well known in the art (see, for example, Sambrook et al. Molecular Cloning: A laboratory manual (Cold Spring Harbor Laboratory Press 1989, latest edition)) which is incorporated herein by reference. Preferably, the peptide encoded by the cDNA is expressed on the surface of a cell or a virus containing the cDNA. For example, cDNA can be cloned into a phage vector wherein, upon expression, the encoded peptide is expressed as a fusion protein on the surface of the phage. Phage display technology was used to identify peptide and protein sequences that bind Angiostatin protein or Endostatin protein, and also to identify peptides that mimic the effector binding sites of effector molecules that interact with Angiostatin protein and Endostatin protein. Materials and Methods Phage Display Libraries The Ph.D. -7 phage display library (New England BioLabs Cat #8100), a combinatorial library consisting of random peptide 7-mers. was screened for 7 amino acid binding peptides. The Ph.D. -7 phage display library consists of linear 7-mer peptides fused to the pill coat protein of M13 via a Gly-Gly-Gly- Ser flexible linker. The library contains 2.8 x 10 independent clones. The Ph.D. library is useful for identifying targets requiring binding elements concentrated in a short stretch of amino acids. The Ph.D.-C7C library (New England BioLabs Cat # 8120) is a combinatorial library consisting of random peptide 7- mers flanked by cysteine residues that under non-denaturing conditions are disulfide bonded resulting in the display of cyclized peptides. In non-reducing conditions, the cysteines form a disulfide bond resulting in each peptide being constrained in a disulfide loop. The library contains 3.7 x 10 independent clones that like the Ph.D. -7 library the peptides are fused to the pill coat protein of M13 via a Gly-Gly-Gly-Ser flexible linker. Constrained libraries are useful in the identification of structural epitopes. The Ph.D.-C7C library was screened for the binding of 7 amino acid cyclized peptides. This particular library was selected because it contains representatives of all possible 7 mer sequences and is also a well characterized library. In addition, the short target sequences typically bind with few high affinity interactions that j 4 allow the identification of strong interactions. In summary, the peptides in this library allow for binding such that peptides bind with greater affinity thereby increasing the likelihood of mimicking the natural ligand of the target protein. Phage Selection The phage display libraries were screened following the manufacturers' recommendations. Approximately lOOμg/ml of recombinant human Angiostatin protein. Kl-4 protein, or recombinant human Endostatin protein w ere coated overnight onto 6-mm tissue culture plates at 4°C in a humidified container. In the first round of panning approximately 2x10 phage were incubated on the protein coated plate for 60 minutes at room temperature while rocking gently. The plates were washed 6 times using TBS (50mM Tris-HCl (pH 7.5), 150 mM NaCl) containing 0.1% Tween 20. The binding phage were collected and amplified following elution using lOOμg/ml of the target protein. Secondary and tertiary pannings were performed as for the primary screen except the TBS washing buffer contained 0.5% Tween 20. Sequencing of Angiostatin-Related Binding Peptides Following the tertiary screening, 10- 12 individual colonies of phage-infected bacteria were picked at random, the phage DNA was isolated and subjected to automated dideoxy sequencing. The sequence of the displayed peptides were deduced from the DNA sequence. Results Peptides presented below in Tables 7-10 were identified as linear or cyclized peptides that bind Angiostatin protein or Endostatin protein. Table 7 Linear Peptides Binding Angiostatin Protein Table 8 Cyclized Peptides Binding Angiostatin Protein Table 9 Linear Peptides Binding Endostatin Protein Peptide Amino Acid Sequence SEQ ID NO: E15 H K R P R N N G G G S SEQ ID NO: 16 E12 T K H R A G R G G G S SEQ ID NO: 17 E13 W H R S V W K G G G S SEQ ID NO: 18 E14 S P Q P F E E G G G S SEQ ID NO: 19 E16 F T E P T H K G G G S SEQ ID NO: 20 E17 K D Y A L P P G G D S SEQ ID NO: 21 E18 S K I A.P I M G G G S SEQ ID NO: 22 E20 W R Q T R K D G G G S SEQ ID NO: 23 E22 G K P M P P M G G G S SEQ ID NO: 24 E37 C T H W H K R C G G G S SEQ ID NO: 25 Table 10 Cyclized Peptides Binding Endostatin Protein Peptide Amino Acid Sequence SEQ ID NO: E41 C S L T P H R Q C G G G S SEQ ID NO: 26 E45 C E K E K P M T C G G G S SEQ ID NO: 27 E48 C A P P G L A R C G G G S SEQ ID NO: 28 EXAMPLE 2 Identification of Binding Peptides that Preferentially Bind Angiostatin protein over Plasminogen Both the linear (Ph.D. -7) and constrained (Ph.D.- C7C) libraries as described in Example 1 were screened for Angiostatin protein specific binding clones: phage that preferentially bind to Angiostatin protein as opposed to plasminogen. Materials and Methods Four rounds of screening were performed on both libraries as follows: Round 1 •2x10 phage bound to Angiostatin protein coated plate •plated washed 10 times •eluted phage with 100/xg/ml plasminogen •plated washed 10 times •eluted phage with lOOμg/ml Angiostatin protein Kl- 4 •amplified the Angiostatin protein eluted phage Round 2 •2x10 amplified primary screen Angiostatin protein eluted phage bound to Angiostatin protein coated plate •plated washed 10 times •eluted phage with lOOμg/ml plasminogen plated washed 10 times eluted phage with lOOμg/ml Angiostatin protein Kl-4 •amplified the Angiostatin protein eluted phage Round 3 •2x10 amplified secondary screen Angiostatin protein eluted phage bound to Angiostatin protein coated plate •plated washed 10 times •eluted phage with 200μg/ml lys-plasminogen •plated washed 10 times •eluted phage with lOOμg/ml Angiostatin protein Kl- 4 •amplified the Angiostatin protein eluted phage Round 4 •2x10 amplified tertiary screen Angiostatin protein eluted phage bound to Angiostatin protein coated plate •plated washed 10 times •eluted phage with 200/zg/ml lys-plasminogen •plated washed 10 times •eluted phage with lOOμg/ml Angiostatin protein Kl- 4 Eluted phage was titrated and plated at approximately 75 pfu per plate. 24 individual plaques were picked from the linear (clones PAL 49 to PAL-72) and constrained (clones PAC- 73 to PAC-96) libraries and the phage amplified. Untitrated phage were assayed for their ability to bind to Angiostatin protein and plasminogen in an ELISA assay. Four fold dilutions of phage ranging from 1 :4 to 1 :65 536 were tested. Several phage were identified as have preferential binding to Angiostatin protein as compared to plasminogen. These phage were selected for further analysis. Table 11 Linear Peptides that Preferentially Bind to Angiostatin protein over Plasminogen Table 12 Cyclized Peptides that Preferentially Bind to Angiostatin protein over Plasminogen EXAMPLE 3 Comparison of Angiostatin-Related Binding Peptides using Phage Display Technology and ELISA Assays A modified ELISA assay was used to determine specificity of binding of the phage to the target protein as recommended by New England BioLabs. Plates coated with the target proteins (Angiostatin protein, Endostatin, plasminogen) were incubated with 4-fold serial dilutions of the phage from approximately 6.25x 10 to 2 10 3 phage particles in 96-well plates. The plates were washed 6 times with TBS containing 0.5% Tween 20 followed by incubation with 1 :5000 diluted HRP- conjugated anti-M13 antibody (Pharmacia # 27-941 1-01). The plates were washed 6 times with TBS containing 0.5% Tween 20 followed by incubation with ABTS (2,2 3 -AZINO-bis(3- ETHYLBENZ-THIAZOLINE-6 SULFONIC ACID)) Peroxidase substrate solution at room temperature for 10-60 minutes. The plates were read at 410nm using a Molecular Devices Spectra MAX 250 microplate reader and SOFTmax® Pro software. As shown in Figures 4 and 5, the peptides selected using phage display technology, preferentially bound to target proteins Angiostatin protein over plasminogen. EXAMPLE 4 Identification of Proteins Bearing Sequence Homology to Peptides Identified as Binding Angiostatin protein or Endostatin protein A protein database was searched for proteins that share sequence homology with the peptides identified previously as binding Angiostatin protein and Endostatin protein (Al-Al l, E12-E22, A25-A36, E37-E48, PAL-49, 51 , 54, 56, 66, 69, 70, and PAC-77, 78, 82, 88 and 91). Because of the short length of the peptides (the shorter the sequence used in a search the lower the specificity) a significant number of proteins that shared homology with the identified peptides were found. A selection of the peptides with the highest homology or which appear to be biologically interesting are provided in Tables 13 and 14. The selection of proteins with the highest homology with the PAL and PAC peptides or which appear to be biologically interesting are provided in Tables 15 and 16. The homology searches were conducted using the FAST A sequence similarity search. The peptide sequences were queried against the SwissProt data base using the default setting (ktup 2, and BLOSUM50 for the scoring matrix). The searches were conduced using the world wide web at site http://www.fasta.genome.ad.jp/. as described by W.R. Pearson & D.J. Lipman PNAS 85:2444-2448 ( 1988), which is incorporated in its entirety herein by reference. Table 13 Search Results for Homologies Against the 7 amino acid Peptide Sequences Table 14 Search Results for Homologies Against the 7 Amino Acid Peptide Plus the GGGS Linker Sequence * The constrained peptides were 13 amino acids because of the 2 cysteines i.e. C-XXXXXXX-CGGGS. An additional selection of peptides having high homology and appearing biologically interesting, are provided in Tables 15 and 16. Table 15 Search Results for Homologies Against the 7 amino acid Peptide Sequences Table 16 Search Results for Homologies Against the 7 Amino Acids Plus the GGGS Linker Sequence * The constrained peptides were 13 amino acids because of the 2 cysteines i.e. C-XXXXXXX-CGGGS. EXAMPLE 5 Angiostatin Protein and Endostatin Protein Interaction with Tropomyosin Based on the rationale that the peptides that bound to Angiostatin protein or ENDOSTATIN protein represent the binding domains of larger proteins that bind Angiostatin and/or Endostatin proteins, it was theorized that Angiostatin protein and/or Endostatin protein binding peptides and proteins would share common motifs that are recognized by corresponding anti- peptide antibodies. Consequently, a HUVEC expression library was screened with antibodies against the A 10 and E37 peptides (A 10 peptide binds Angiostatin protein while E37 peptide binds Endostatin protein, see Examples 1 and 2). In doing so. multiple clones that code for human tropomyosin were isolated. Though not wishing to be bound by the following theory, it is believed that proteins and peptides that bind Endostatin protein comprise tropomyosin and, that through this interaction, exert their angiogenic effects. Tropomyosin was identified based on the DNA sequence of the isolated clone. The 5 prime and 3 prime ends of the clone being recognized by the A10 and E37 antibodies were determined by routine DNA sequencing techniques. The obtained sequences were then 'BLASTED' against the GeneBank database (of DNA sequences) and a high degree of sequence similarity was observed between both the 5 prime and 3 prime end sequences of our clone and human tropomyosin mRNA. The BLAST searches were conducted using the WWW site at http://www.blast.genome.ad.jpl using the default setting (scoring matrix BLOSUM62). Results of the BLAST searches are provided below. 5 Prime End Blast Results High Probability Sequences producing High-scoπng Segment Pairs: Score P(N) N gb:HUMTRO Human tropomyosin mRNA, complete cds. 342 2.1e-20 1 gb:S78854 alpha-tropomyosin [rabbits, New Zealand whi... 309 l.le-17 1 gb:SSCATROP S.scrofa mRNA for cardiac alpha tropomyosin. 3024.3e-17 1 gb:HUMTROPA2 Human skeletal muscle alpha-tropomyosin (hT... 297 l.le-16 1 gb:RATTMBRlA Rat brain alpha-tropomyosin (TMBr-l) mRNA, ... 293 2.4e-16 1 gb:MMPTMA M.musculus mRNA for skeletal muscle alpha t... 293 2.4e-16 1 gb:MUSTR02IS Mouse tropomyosin isoform 2 mRNA. complete ... 293 2.5e-16 1 gb:RATTR02A Rat alpha-tropomyosm 2 mRNA, complete cds. 293 2.5e-16 1 gb:RATTR03A Rat alpha-tropomyosin 3 mRNA, complete cds. 293 2.5e-16 1 gb:RATTMAl Rat alpha-tropomyosm gene, exons 1-3. 279 3.9e-15 1 gb:AR008277 Sequence 3 from patent US 5753446. 242 8.7e-15 2 gb:AR008281 Sequence 11 from patent US 5753446. 242 8.7e-15 2 gb:RATTROPA Rat smooth muscle alpha-tropomyosin mRNA, c... 268 1.3e-13 1 gb:RNTROASM Rat mRNA for smooth muscle alpha-tropomyosm. 268 1.3e-13 1 gb:A62300 Sequence 3 from Patent W09712982. 228 1.2e-12 2 gb:HUMTRPMYO Human tropomyosin- 1 (TM-beta) mRNA, complet..246 3.1e-l 1 1 gb:HUMTMlE H.sapiens epithelial tropomyosin (TM1) mRNA... 246 3.1e-l l 1 gb:RATTRO01 Rat skeletal muscle beta-tropomyosin and fi... 237 2.2e-10 1 gb:A62298 Sequence 1 from Patent W09712982. 234 4.7e-10 1 gb:AR018138 Sequence 1 from patent US 5780609. 234 4 8e-10 1 gb:AR008278 Sequence 5 from patent US 5753446. 230 l . le-09 1 gb:AMTTROPOX Ambystoma mexicanum tropomyosin mRNA, compl. 229 1.3e-09 1 gb:AB005878 Nicotiana tabacu mRNA for BYJ15, paπial cds. 228 1.4e-09 1 gb:ABO05879 Nicotiana tabacum mRNA for BYJ6, partial cds. 228 1.4e-09 1 gb:DMELAST D.melanogaster mRNA for elastin-like protein. 228 1.4e-09 1 gb:TEZ86120 T.evansi mRNA, clone Q16R1. 228 1.6e-09 1 gb:MMBTROP M.musculus mRNA for beta-tropomyosin. 228 1.6e-09 1 gb:MUSBETATRO Mouse beta-tropomyosin 2 mRNA. complete cds. 228 1.6e-09 1 gb:MMTPMYOB Mus musculus gene for beta-tropomyosin. 228 1.6e-09 1 gb:AB002449 Homo sapiens mRNA from chromosome 5q21-22. ... 228 1.6e-09 1 gb:OSCHINDPR O.sativa mRNA for chilling-inducible protein. 228 1.7e-09 1 gb:114842 Sequence 10 from patent US 5455167. 228 1.7e-09 1 gb:I65496 Sequence 6 from patent US 5667997. 228 1.7e-09 1 gb:ATCYC2B A.thaliana (Columbia) cyc2b mRAN for cyclin... 228 1.7e-09 1 gb:I79511 Sequence 2 from patent US 5707809. 228 1.7e-09 1 gb:AF060519 Cuphea hookeriana 3-ketoacyl-ACP synthase (... 228 1.7e-09 1 gb:MUSTROB Mouse skeletal muscle beta tropomyosin mRNA... 228 1.7e-09 1 gb:AF058696 Homo sapiens cell cycle regulatory protein ... 228 1.8e-09 1 gb:MSASET2MR M.sativa mRNA for ASET2. 220 8.9e-09 1 gb:AB005877 Nicotiana tabacum mRNA for BYJ14, partial cds. 219 9.0e-09 1 gb:S71728 truncated protein {frame 1, multiple clonin... 198 9.4e-09 1 gb:I50126 Sequence 19 from patent US 5641876. 198 l . le-08 1 gb:I50132 Sequence 25 from patent US 5641876. 198 l.le-08 1 gb:I50128 Sequence 21 from patent US 5641876. 198 l. le-08 1 gb:I50133 Sequence 26 from patent US 5641876. 198 1.2e-08 1 gb:PSP54MRNA Pi sum sativum mRNA for P54 protein. 218 1.4e-08 1 gb:CHKTRPMYB Chicken skeletal muscle beta-tropomyosin mR... 216 2.1e-08 1 gb:CHKTROBRTl Chicken beta-tropomyosin 1 (BRT-1 ) mRNA, co... 216 2.2e-08 1 gb:I82448 Sequence 60 from patent US 5712143. 213 2.2e-08 1 gb:CHKTROSS01 Chicken tropomyosin beta subunit gene, exon... 216 2.2e-08 1 gb:AR013938 Sequence 1 from patent US 5773225. 193 3.4e-08 1 gb:AR016808 Sequence 33 from patent US 5777200. 213 3.7e-08 1 gb:AR020834 Sequence 33 from patent US 5789214. 213 3.7e-08 1 gb:I38463 Sequence 33 from patent US 5614395. 213 3.7e-08 1 gb:I56938 Sequence 33 from patent US 5650505. 213 3.7e-08 1 gb:I59804 Sequence 33 from patent US 5654414. 213 3.7e-08 1 gb:I75131 Sequence 33 from patent US 5689044. 213 3.7e-08 1 gb:NTZ82982 N.tabacum mRNA for caffeoyl-CoA O-methyltra... 213 3.9e-08 1 gb:MZEAGAMOU Zea maize AGAMOUS homologue mRNA, complete 213 3.9e-08 1 gb:AF030383 Cucumis melo var. markuwa Markino ADP-gluco... 213 4.0e-08 1 gb:CLCYCBMR C.longicaudatus mRNA for cychn B. 213 4.0e-08 1 gb:CPU69698 Cryptospoπdium parvum heat shock protein 1... 21 1 6.2e-08 1 gb:S81027 Msr-1 10=EN protein binding gene/engrailed n... 208 l . le-07 1 gb:HUMTROPA Human fibroblast muscle-type tropomyosin mR... 207 1 3e-07 1 gb:CHKATRO Chicken fast-twitch alpha-tropomyosin mRNA.... 207 1.3e-07 1 gb:HSTPMYOB Human mRNA for skeletal beta-tropomyosin. 207 l .3e-07 1 gb:QULTROAB Japanese quail alpha-tropomyosin mRNA, comp... 207 1.3e-07 1 gb:I94990 Sequence 9 from patent US 5731411. 188 1.3e-07 1 gbrCHKAFTROPl Chicken alpha-tropomyosm gene, exons la. 2... 207 1.4e-07 1 gb:GGTMElA2A G.gallus gene for tropomyosin (alpha isofor... 207 1.4e-07 1 gb:CCTPMY01 Quail gene for alpha-tropomyosin, exons 1-3... 207 1.4e-07 1 gb:QULTROAA Japanese quail alpha-tropomyosm mRNA, comp... 206 1.7e-07 1 gb:MAU29167 Mesocπcetus auratus tropomyosιn-1 mRNA, co... 205 2 0e-07 1 gb:S71730 influenza virus hemagglut in 5' epitope ta... 198 2.0e-07 1 gb:DMIPOU D.melanogaster I-POU mRNA for a POU-domain ... 205 2.1e-07 1 gb:SYNPLKRA Cloning vector pUC128 DNA, polyhnker region. 198 2.4e-07 1 gb:SYNPLKRB Cloning vector pUC129 DNA, polyhnker region. 198 2.6e-07 1 gb:S71742 influenza virus hemagglutmin 5' epitope ta... 198 2.8e-07 1 gb: A59058 Sequence 1 from Patent WO9703200. 203 3. le-07 1 gb:GGINTB3 G.gallus mRNA for integπn beta3. 203 3.2e-07 1 gb:STRSTRH Streptococcus pneumomae beta-N-acetylhexos... 203 3.3e-07 1 gb:S71745 influenza virus hemagglutinin 5' epitope ta... 198 3.5e-07 1 gb:RANATROA R.temporaπa skeletal muscle alpha-tropomyo... 201 4.5e-07 1 gb:AF067142 Cloning vector pSFI polyhnker, complete po... 198 4.6e-07 1 gb:AR016514 Sequence 24 from patent US 5776746. 198 6.0e-07 1 gb:CVU61229 Cloning vector pKRX. complete sequence. 199 7.3e-07 1 gb:AR008443 Sequence 70 from patent US 5753488. 198 7.8e-07 1 gb:I87435 Sequence 70 from patent US 5703221. 198 7.8e-07 1 gb:PFL17187 Platichthys flesus Ki-ras gene (exons 1, 2,... 198 7.9e-07 1 gb:DMFRIZZ3 D. melanogaster fπzzled gene exons 3 and 4. 198 8.4e-07 1 gb:SMOFMTRMYA Salmo salar fast myotomal muscle tropomyosi... 198 8.4e-07 1 gb:CHKTROPB Chicken tropomyosin (clone CTm7) mRNA, comp... 198 8.5e-07 1 gb:A45456 Sequence 1 from Patent EP0607925. 198 8.5e-07 1 gb:I17500 Sequence 1 from patent US 5489743. 198 8.5e-07 1 gb:D88747 Arabidopsis tha ana mRNA for AR401, comple... 198 8.6e-07 1 gb:NTY !4032 Nicotiana tabacum mRNA for ferredoxin-NADP ... 198 8.6e-07 1 gb:CHKTROPA Chicken tropomyosin (clone CTm4) mRNA, comp... 198 8.6e-07 1 gb:MPCAM M.pyπfera mRNA for calmoduhn. 198 8.7e-07 1 gb:PFL17188 Platichthys flesus Ha-ras gene (exons 1 to 4). 198 8.7e-07 1 gb:ORZPC Oryzias latipes mRNA for photolyase. comple... 198 8.8e-07 1 3 Prime End Blast Results Sequences producing High-scoring Segment Pairs: Score P(N) N gb:HSAJ147 Homo sapiens mRNA for alpha-tropomyosin (3'... 700 1.9e-110 4 gb:HSALPTROP Homo sapiens mRNA for alpha-tropomyosin. 1055 1.4e-96 2 gb:HSTROISOA H.sapiens tropomyosin isoform mRNA. complet... 1012 2.9e-76 1 gb:MUSTR02IS Mouse tropomyosin isoform 2 mRNA. complete ... 2264.3e-33 4 gb:RATTMA6 Rat alpha-tropomyosin gene, exon 12. 267 1.9e-28 3 gb:RATTR05A Rat alpha-tropomyosin 5a mRNA, complete cds. 267 7.9e-24 3 gb:RATTR05B Rat alpha-tropomyosin 5b mRNA, complete cds. 267 7.9e-24 3 gb:RATTR02A Rat alpha-tropomyosin 2 mRNA, complete cds. 267 8.7e-24 3 gb:RATTR03A Rat alpha-tropomyosin 3 mRNA, complete cds. 267 8.7e-24 3 gb:RATTMBR3A Rat brain alpha-tropomyosin (TMBr-3) mRNA, ... 267 2.2e-23 3 gb:RATTROPA Rat smooth muscle alpha-tropomyosin mRNA, c... 206 5.9e-18 3 gb:RNTROASM Rat mRNA for smooth muscle alpha-tropomyosin. 206 5.9e-18 3 gb:CHKAFTROP6 Chicken alpha-tropomyosin gene, exon 9c, 9d... 273 2.9e-12 1 gb:GGTME9C9D G.gallus gene for tropomyosin (alpha isofor... 273 2.9e-12 1 gb:HSTROPM Human mRNA (exon 6-9 part.) for smooth muse... 224 3.6e-08 1 gb:HUMTROPA4 Human skeletal muscle alpha-tropomyosin (hT... 224 3.6e-08 1 gb:HUMTRO Human tropomyosin mRNA, complete cds. 224 3.7e-08 1 gb:CCTPMY13 Quail gene for alpha-tropomyosin, exon 13. 146 0.13 1 gb:DMU66884 Drosophila melanogaster cubitus interruptus... 133 0.83 1 gb:CEZK666 Caenorhabditis elegans cosmid ZK666, comple... 132 0.88 1 gb:AC004002 Human BAC clone RG356F09 from 7p21, complet... 132 0.88 1 EXAMPLE 6 Identification of Peptides Capable of Binding Endostatin protein As a result of the findings of the above experiments, nine clones from a HUVEC lambda Uni-ZAP XR cDNA library were purified based on the observation that they express a protein that is recognized by polyclonal antibodies raised against the A10 and E37 peptide (see Examples 1 and 2). Sequencing data showed that 6 of the 9 code for tropomyosin. The sequencing reaction for one clone failed but restriction analysis showed that it also codes for tropomyosin. Thus 7 of the 9 clones code for tropomyosin. One clone codes for human glyceraldehyde 3- phosphate dehydrogenase (GAPDH). The GenBank accession number for this sequence is HUMG3 PDC. The other clone shares homology with (cr36cl0.xl) Jia bone marrow stroma Homo sapiens cDNA clone. The GenBank accession number for this sequence is AI755161. Analysis of the DNA sequences has shown that the 5 ' end of one clone, PL26/2. codes for GAPDH while the 3' end codes for an SH 3 domain binding glutamic acid-rich-like protein (SH# BGRL. GeneBank accession number AFO42081). Though not wishing to be bound by the following theory, it is thought that it is the anti-E37 antibodies recognize tropomyosin with greater affinity than the anti-AlO. Using an antibody that recognizes tropomyosin the interaction of tropomyosin with Endostatin protein is analyzed. Also, FACS analysis is conducted to demonstrate the location of tropomyosin and to show its hypothesized location on the surface of endothelial cells. Additional experiments blocking the binding of Endostatin protein to the surface of HUVEC cells and comparable assays for Angiostatin protein are performed. Further experiments involving immunoprecipitations using antibodies against Angiostatin protein and/or Endostatin protein are performed to confirm a receptor/protein pairing based on resulting tropomyosin co-precipitating and vise versa. Confirmation of binding, for example binding of Endostatin protein to tropomyosin is done by expressing Endostatin protein as a glutathione S-transferase (GST) fusion protein in E. coli. The Endostatin -GST is bound to an affinity matrix and incubated with HUVEC extracts. Following washing, the proteins are eluted and run on an SDS-PAGE gel and western blotted probing with anti-tropomyosin antibodies. Interaction of Endostatin protein and tropomyosin results in the detection of tropomyosin on the western blot. The reverse of this experiment is also conducted using tropomyosin-GST and a crude Endostatin protein containing lysate (Picia broth perhaps). In vivo experiments for determining the role of tropomyosin involved in the activity of Endostatin protein with regard to angiogenesis are also performed. In one such experiment, anti-tropomyosin antibodies are co-administered with Endostatin protein. Confirmation of tropomyosin's interaction with Endostatin protein results from a negation of anti-tumor activity typically resulting from Angiostatin protein or Endostatin protein. In another type of in vivo experiment, tropomyosin is recombinantly expressed and co-administered with either Angiostatin protein or Endostatin protein to observe the effect on anti-tumor activity usually associated with Angiostatin protein or Endostatin protein In another experiment, labeled Angiostatin protein or Endostatin protein (i.e. biotin-labeled Endostatin protein) is administered to tumor bearing mice in order to determine the fate of the labeled protein (i.e. binding sites). In another aspect of the present invention, immunohistochemicial techniques are employed to see if the labeled protein and tropomyosin co-localize. As is known in the art, tropomyosin is involved in the formation of fibers that play a key role in cell shape and motility and therefore in yet another aspect of the invention, immunoflorescence is used to study the effects of Angiostatin protein and/or Endostatin protein on cellular organization normally controlled by tropomyosin. EXAMPLE 7 Interaction of Laminin Protein and Angiostatin protein The following experiment was conducted in order to identify a potential receptor, or molecule comprising a receptor or binding partner for Angiostatin protein. Materials and Methods Peptides obtained by biopanning against Angiostatin protein were edited to remove multiple copies of sequences. This left the following sequences, arranged into specific classes of sequences. I. Data Table 17 Linear Peptide Sequences Capable of Binding Angiostatin protein Table 18 Cyclized Peptide Sequences Capable of Binding Angiostatin protein II. Data Base Searches The obvious searches of sequence data bases did not identify any human proteins that were potential targets of Angiostatin protein. In particular, searches were made for proteins containing the following sequences: WSLE SEQ ID NO: 104 TLE SEQ ID NO: 105 WSYE SEQ ID NO: 106 KCCY SEQ ID NO: 107 TLQVL SEQ ID NO: 108 None of these motifs were present in fibrinogen, the natural substrate for plasminogen. A closer look for fibrinogen peptides with similarity to Angiostatin protein-selected peptides was carried out. As outlined below, this search identified a number of places in the fibrinogen alpha chain with significant similarity to the selected peptides. Because of the presence of fibrinogen sequences with similarities to the selected peptides, additional data base searches were made and one, ERVN (SEQ ID NO: 109) identified a tetrapeptide present in the laminin beta-1 chain. However, a closer look at laminin provides additional weight to the possibility that Angiostatin protein binds laminin beta-1 protein (see below). III. Fibrinogen The natural substrate for plasminogen is fibrin. Several studies have shown that fragments of plasminogen containing intact kringle domains bind to fibrin. For instance, Wu et al. (J. Biol. Chem. 265; 19658-64; 1990) showed that a plasminogen fragment containing kringles 1-3 binds to fibrin but with affinity less than a fragment containing kringles 1-5. They showed that kringle 4 does not bind to fibrin. The binding of plasminogen to fibrin involves interactions with lysines on fibrin and can be inhibited by lysine analogues. Only kringle 3 appears to be devoid of a ly sine-binding motif (Cao et al., J. Biol. Chem.271; 29. 461-29467; 1996) The large number of lysines in the Angiostatin protein selected peptides is consistent with the known lysine- binding properties of plasminogen and plasminogen fragments containing intact kringle domains (lysine affinity is k4>kl>k2>k3 (none)). The plasminogen-binding sites on fibrin have not yet been identified (for example see Weisel et al., 1994; J. Mol. Biol. 235; 1117- 1135). However, there are a number of sequences in fibrinogen with significant homology to the selected peptides. These sequences are potentially involved in plasminogen binding and include: Fibrinogen alpha 91 SLFEYGK SEQ ID NO: 110 WSLEWQK SEQ ID NO : 98 Fibrinogen alpha 433 LVTSK SEQ ID NO: 111 WSLETTK SEQ ID NO: 100 SYEWSK SEQ ID NO: 97 WSLEQSK SEQ ID NO: 99 TLESTK SEQ ID NO: 95 Fibrinogen alpha 477 EV K SEQ ID NO: 112 WSLETTK SEQ ID NO: 100 WSYEWSK SEQ ID NO: 97 WSLEQSK SEQ ID NO: 99 WTLESTK SEQ ID NO: 95 These results provide significant and important information about the plasminogen binding sites on fibrinogen. IV. Laminin beta-1 Chain Laminin beta- 1 chain is 1786 amino acids long, making the odds of it having any tetrapeptide by random chance about 1%. The amino acid sequence of laminin protein is set forth in Figure 6 A (SEQ ID NO: 1 13) and the nucleotide sequence is set forth in Figure 6B (SEQ ID NO: 114). There are three motifs corresponding to Angiostatin protein selected peptides in a single 60 amino acid long region. (See Figure 7). The convergence of three putative contact motifs in a very small region of laminin strongly supports the possibility that Angiostatin protein binds to laminin protein. V. Laminin beta-1 Chain Domain Structure Laminin is a heterotremeric molecule with one each of the alpha, beta and gamma chains making up the molecule. The three chains form triple-helical coiled-coils at several places within the molecule. The putatative binding sites are in a portion of the laminin beta-1 chain designated as Domain II. The molecule is a complex, multi-domain component of the basement membrane organized as follows: Amino Acid Range Characterization 1-21 signal sequence 22-270 N-terminal domain 271-540 4=1/2 EGF-like domains (4 complete, 1 partial) 541-771 laminin domain IV 772-1178 8 EGF like domains 1179-1397 domain II 1216-1315 coiled-coil (approx 150 Angstroms long) 1353-1388 coiled-coil (approx 54 Angstroms long) 1398-1430 domain alpha 1431-1786 domain I 1442-1481 coiled-coil (approx 510 Angstroms long) The putative binding sites are in domain II. The first two sites are in the part of domain II between the two coiled coils (the second binding site is just prior to the start of the second coiled coil). The third site is at the very end, but within, the second coiled coil region (that is consistent with the breaks in the this consensus sequence - to be expected in an alpha helical region). Consequently, sites 2 and 3 are as much as 55 Angstroms apart, separated by most of the coiled coil. VI. Mouse Laminin Mouse laminin is commercially available. Mouse laminin beta-1 chain is 90% identical and 94% similar to human laminin. In the putative binding sites, only the first amino acid of the first site is different. Consequently, if Angiostatin protein binds to human laminin, it will most likely also bind to mouse laminin. VII. Molecular Mechanism of Angiostatin protein Screening of a phage-displayed library of peptides has identified peptides with similarity to sequences in fibrinogen and laminin beta-1 chain protein. It is believed that Angiostatin protein has an affinity for laminin beta 1 chain protein. It is further believed that laminin protein comprises a receptor, or a molecule comprising a receptor or binding partner of Angiostatin protein. Using an antibody that recognizes laminin protein the interaction of laminin protein with Angiostatin protein is analyzed. Also, FACS analysis is conducted to demonstrate the location of laminin protein and to show its location on the surface of endothelial cells. Additional experiments blocking the binding of Angiostatin protein to the surface of HUVEC cells and comparable assays for Endostatin protein are performed. Further experiments involving immunoprecipitations using antibodies against Angiostatin protein and/or Endostatin protein are performed to confirm a receptor/protein pairing based on resulting laminin protein co-precipitating and vice versa. EXAMPLE 8 In Vitro Interaction of Tropomyosin and Endostatin Protein The following experiment was conducted in order to assess the interaction of tropomyosin and Endostatin protein. Materials and Methods In this experiment the wells of a 96 well plate were either coated with 5 μg/ml of Endostatin protein or BSA protein The wells were incubated in the presence of serial dilutions of E coli lysate that either containing or not containing tropomyosin protein. The wells were washed and incubated with anti- tropomyosin antibodies followed by anti-mouse IgG AP conjugated antibodies and developed using KPL Blue Phos micro well phosphatase solution. The OD 635 was measured after a 1 hour incubation at RT and the results plotted on a graph (see Figure 8). Four conditions were tested: 1) BSA coated well + E. coli lysate containing tropomyosin. 2) Endostatin protein coated well + E. coli lysate containing tropomyosin 3) Endostatin protein coated well + E. coli lysate containing no tropomyosin 4) BSA coated well + E. coli lysate containing no tropomyosin Results and Conclusion As shown by the results in the graph, (Figure 8) when E. coli lysate containing tropomyosin is incubated on a Endostatin protein coated well (sample 2) considerably more tropomyosin binds than when the well is BSA coated or when there is no tropomyosin contained in the E.coli lysate. The higher the OD635 the more tropomyosin is binding the plate. The results of this experiment therefore demonstrate positive binding interaction between tropomyosin and Endostatin protein. EXAMPLE 9 In Vivo Interaction of the E37 Peptide and Endostatin Protein The following experiment was conducted to determine the interaction of E37 peptide and Endostatin protein. Materials and Methods A brief description of the B16BL6 experimental metastasis assay is provided below. This assay is well known to those skilled in the art, for more detail see United States Patent Application Serial No. 09/413,049 and International Patent Application number PCT/US99/11418. 5xl0 4 B 16BL6 cells in 200μl of PBS were injected into C57BL/6J mice via the tail vein. Three days post injection treatment was started. There were 8 groups receiving treatments as described below: 1) citrate phosphate/PBS buffer 2) 30μg Endostatin protein (in lOOμl PBS) 3) 30μg Endostatin protein (in 200μl PBS) 4) 30μg Endostatin protein + 50x molar excess of control peptide (in 200μl PBS) 5) 30μg Endostatin protein + 250x molar excess of control peptide (in 200μl PBS) 6) 30μg Endostatin protein + lOx molar excess of E37 peptide (in 200μl PBS) 7) 30μg Endostatin protein + 50x molar excess of E37 peptide (in 200μl PBS) 8) 30μg Endostatin protein + 250x molar excess of E37 peptide (in 200μl PBS) Doses were administered daily for eleven days posterior to the thoracic cavity subcutaneously. All mice were sacrificed, the lungs removed and the number of surface metastases in each animal were counted under a stereo microscope. Results A summary of the results of this experiment are listed below, and detailed results of this experiment are provided in Figure 9 wherein the number of metastases on each lung is listed, as well as the mean, standard deviation, T/C and the results of a 2-tailed T-test. The results are graphically described in Figure 10. Endostatin protein alone inhibited the formation of lung metastasis by -79% 37 Endostatin protein + 50 fold molar excess of the negative control peptide inhibited the formation of lung metastasis by -79% Endostatin protein + 250 fold molar excess of the negative control peptide inhibited the formation of lung metastasis by -73% Endostatin protein + 10 fold molar excess of the E37 peptide inhibited the formation of lung metastasis by -76% Endostatin protein + 50 fold molar excess of the E37 peptide inhibited the formation of lung metastasis by -61% Endostatin protein + 250 fold molar excess of the E37 peptide inhibited the formation of lung metastasis by -21 % Conclusion The current experiment indicates that the E37 peptide and Endostatin protein interact in vivo . We make this assumption on the basis that in the presence of the E37 peptide (but not a random control peptide) the anti-tumor activity of Endostatin protein is inhibited. We conclude from this that the reduced activity of the Endostatin protein in the presence of the E37 peptide is the result of the E37 peptide binding to the Endostatin protein. The effect of the E37 peptide binding to Endostatin protein is that Endostatin can no longer bind its receptor/binding protein, which we contend is tropomyosin. It should be understood that the foregoing relates only to preferred embodiments of the present invention, and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims. The references cited throughout are hereby incorporated by reference in their entireties.

Claims: We claim: 1 . An angiogenesis-inhibiting protein receptor comprising an amino acid sequence comprising SEQ ID NOS: 3- 15, SEQ ID NOS: 31-42 and SEQ ID NOS: 82- 1 13, wherein the angiogenesis-inhibiting protein comprises a protein having a molecular weight of between approximately 38 kilodaltons and 45 kilodaltons as determined by reducing polyacrylamide gel electrophoresis. and having an amino acid sequence substantially similar to that of a plasminogen fragment beginning at approximately amino acid 98 of a plasminogen molecule. 2. A nucleic acid coding the receptor of Claim 1 , having a nucleotide sequence comprising SEQ ID NOS: 43-55 and SEQ ID NOS: 69-80. 3. The angiogenesis-inhibiting protein receptor of Claim 1 , wherein the receptor comprises laminin protein, tropomyosin, and active fragments and homologs thereof. 4. A method of increasing angiogenesis in an individual, comprising administering to an individual an angiogenesis increasing amount of a receptor of Claim 1. 5. A method of identifying an angiogenesis-inhibiting protein receptor comprising: (a) obtaining a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 3- 15, SEQ ID NOS: 31-42 and SEQ ID NOS: 82-1 13; (b) testing said peptide for an ability to bind angiogenesis-inhibiting protein, (c) testing said peptide for an ability to affect angiogenesis-inhibiting protein-mediated angiogenesis, wherein the ability to bind an angiogenesis-inhibiting protein and affect angiogenesis-inhibiting protein-mediated angiogenesis identifies the angiogenesis-inhibiting protein receptor, (d) wherein the angiogenesis-inhibiting protein comprises a protein having a molecular weight of between approximately 38 kilodaltons and 45 kilodaltons as determined by reducing polyacrylamide gel electrophoresis, and having an amino acid sequence substantially similar to that of a plasminogen fragment beginning at approximately amino acid 98 of a plasminogen molecule. 6. The method of Claim 5, wherein the angiogenesis- inhibiting protein receptor comprises laminin protein, tropomyosin. and active fragments and homologs thereof. 7. An angiogenesis-inhibiting protein receptor comprising an amino acid sequence comprising SEQ ID NOS: 16- 28 and SEQ ID NOS: 82-1 13, wherein the angiogenesis-inhibiting protein has a molecular weight of approximately 18 to approximately 20 kilodaltons as determined by non-reducing and reducing gel electrophoresis. and having an amino acid sequence substantially similar to that of an C-terminal fragment of a collagen molecule. 8. A nucleic acid coding the receptor of Claim 7 having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 56-68. 9. The angiogenesis-inhibiting protein receptor of Claim 7 wherein the receptor comprises laminin protein, tropomyosin, and active fragments and homologs thereof. 10. A method of increasing angiogenesis in an individual, comprising administering to an individual an angiogenesis increasing amount of a receptor of Claim 7. 1 1. A method of identifying an angiogenesis-inhibiting protein receptor comprising: (a) obtaining a peptide comprising an amino acid sequence comprising SEQ ID NOS: 16-28 and SEQ ID NOS: 82- 1 13; (b) testing said peptide for an ability to bind angiogenesis-inhibiting protein, (c) testing said peptide for an ability to affect angiogenesis-inhibiting protein-mediated angiogenesis, wherein the ability to bind an angiogenesis-inhibiting protein and affect angiogenesis-inhibiting protein-mediated angiogenesis identifies the angiogenesis-inhibiting protein receptor. (d) wherein the angiogenesis-inhibiting protein has a molecular weight of approximately 18 to approximately 20 kilodaltons as determined by non-reducing and reducing gel electrophoresis, and having an amino acid sequence substantially similar to that of an C-terminal fragment of a collagen molecule. 12. A method of expressing a nucleic acid selected from the group consisting of SEQ ID NOS: 43-80 comprising transfecting the nucleic acid into a vector and host cell system capable of recombinantly producing the protein coded thereby. 13. The method of Claim 1 1 wherein the angiogenesis- inhibiting protein receptor comprises laminin protein, tropomyosin, and active fragments and homologs thereof.

Inventors: MACDONALD NICHOLAS J, SIM KIM LEE, MACDONALD, NICHOLAS, J., SIM, KIM, LEE
Applicants: ENTREMED INC, MACDONALD NICHOLAS J, SIM KIM LEE, ENTREMED, INC., MACDONALD, NICHOLAS, J., SIM, KIM, LEE
Application year: 1999
Main classification: C07K14
IPC codes: A61K35, A61K38, A61K45, A61K48, A61P9, A61P27, A61P29, A61P35, A61P43, C07K14, C12N15, C12Q1, C40B40, C40B50, G01N33